Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of MGCD0103 (MG-0103) Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma

NCT00359086 is registered in ClinicalTrials.gov with Mirati Therapeutics Inc. as lead sponsor.

NCT NCT00359086
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00359086 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of MGCD0103 (MG-0103) Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma
Lead sponsor
Mirati Therapeutics Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2006
Completion date
January 31, 2012
Enrollment
74 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma